4D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and Degeneration meeting, and while there was some deterioration of the injection burden vs. the prior cut, the debate of 4D sacrificing efficacy for safety is over as the results are on par with Adverum Biotechnologies (ADVM), RBC Capital tells investors. The firm says the aflibercept levels are “convincing,” and believes 4D Molecular offers an “enticing” reduction in treatment burden with an “ideal” entry point at the current valuation. RBC Capital has an Outperform rating and $39 price target on the shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- Cautious ‘Hold’ Rating on 4D Molecular Therapeutics Amidst Competitive Market and Investor Concerns
- 4D Molecular Therapeutics: Strong Buy Rating on Promising 4D-150 Gene Therapy Data and Strategic Phase 3 Trials
- Promising Prospects for 4D Molecular Therapeutics: Anticipated Growth in wAMD Treatment and Market Valuation
- 4D Molecular price target lowered to $42 from $46 at BofA
- 4D Molecular price target lowered to $6 from $8 at Morgan Stanley